immunology
The latest news about immunology: headlines, AI summaries and the full story from every source.
- AbbVie Reports Q3 2026 Revenue Beat Driven by Skyrizi and Rinvoq Growth
- Pfizer's Eczema Drug Tilrekimig Shows Strong Results in Mid-Stage Trial
- AbbVie partners with Iambic Therapeutics on multi-year AI drug discovery collaboration
- Owkin partners with Boehringer Ingelheim for AI-driven drug discovery
- Eli Lilly to Acquire Merida Biosciences in $2.88 Billion Deal
- AbbVie Inc. Reports Strong Q2 2026 Performance with Growth Across Key Portfolios
- argenx Acquires Forte Biosciences for $2.2 Billion in Cash
- Forte BioSciences Stock Surges After $2.2 Billion Acquisition Deal with Argenx
- Argenx Agrees to Acquire Forte Biosciences in $2.2 Billion Deal
- argenx agrees to acquire Forte Biosciences for $2.2 billion
- AbbVie to Acquire Apogee Therapeutics for $135.11 per Share
- AbbVie to Acquire Apogee Therapeutics; Other Notable Press Releases
- AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Strengthen Immunology Portfolio
- AbbVie Announces Acquisition of Apogee Therapeutics for $10.9 Billion
- Biogen Acquires RayThera for Up to $1 Billion
- ADMA Biologics Receives FDA Approval to Expand ASCENIV Label for Pediatric Patients
- Pfizer Begins Phase 3 Trial for New Pneumococcal Vaccine in Infants
- UCB Acquires Candid Therapeutics for $2.2 Billion
- AbbVie Exceeds First-Quarter 2026 Earnings and Raises Full-Year Forecast